Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pancreatic and gastric lipases are key digestive enzymes responsible for the breakdown of dietary fats. Pancreatic lipase is secreted by the pancreas into the small intestine where it catalyzes the hydrolysis of triglycerides into monoglycerides and free fatty acids. This process requires bile salts for emulsification and colipase as a cofactor. Gastric lipase is secreted by chief cells in the stomach; it initiates lipid digestion under acidic conditions before chyme enters the small intestine. Both enzymes belong to distinct gene families but share an alpha/beta-hydrolase fold structure with a catalytic triad at their active site. Deficiencies or dysfunctions in these enzymes can result in malabsorption syndromes or contribute to diseases like pancreatitis. Pharmacological inhibition—most notably by drugs like orlistat—targets these enzymes therapeutically to reduce fat absorption as an anti-obesity strategy but may cause gastrointestinal side effects due to unabsorbed fats[1][4][5][6].
Inhibition of enzymatic hydrolysis of dietary triglycerides in the gastrointestinal tract[5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pancreatic lipase and gastric lipase.